A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer: Trial in progress update
医学
子宫内膜癌
卵巢癌
内科学
肿瘤科
双特异性抗体
抗体
癌症
免疫学
单克隆抗体
作者
Joyce F. Liu,David M. O’Malley,Els Van Nieuwenhuysen,Roisin E. O’Cearbhaill,Sara Bouberhan,Kathleen N. Moore,June Y. Hou,Erika Hamilton,Suk‐Young Yoo,Bin Wang,Mary Peterman,Tamara Schmidt,David A. Knorr,Israel Lowy,Thomas S. Uldrick,Elizabeth Miller
PDF的下载单位、IP信息已删除
(2025-6-4)
null
无极微光
吃葡萄不吐葡萄皮
学霸业
GingerF
Criminology34
Gp1983
Elsevier大王
My_magnum_opus
Chinno
sanvva
deli
v0id
华无剑
李小白
Nole
lx
麦咕咕
EeeeW
渡人舟
皖公网安备34019202002308
